WarnkeCStüveOHartungHP. Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat2011; 7: 519–527.
2.
MehlingMBrinkmannVAntelJ. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology2008; 71(16): 1261–1267.
3.
MehlingMJohnsonTAAntelJ. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology2011; 76(8Suppl. 3): S20–S27.
4.
ChiariniMSottiniABertoliD. Newly produced T and B lymphocytes and T-cell receptor repertoire diversity are reduced in peripheral blood of fingolimod-treated multiple sclerosis patients. Mult Scler2015; 21(6): 726–734.
5.
FriessJHeckerMRochL. Fingolimod alters the transcriptome profile of circulating CD4+ cells in multiple sclerosis. Sci Rep2017; 7: 42087.
6.
ThomasKSehrTProschmannU. Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation. J Neuroinflammation2017; 14(1): 41.
7.
SatoDKNakashimaIBar-OrA. Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis. J Neuroimmunol2014; 268(1–2): 95–98.
8.
WarnkeCOlssonTHartungHP. PML: The dark side of immunotherapy in multiple sclerosis. Trends Pharmacol Sci2015; 36(12): 799–801.
9.
BartschTRempeTWredeA. Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate. Ann Neurol2015; 78(4): 501–514.
10.
RosenHStevensRCHansonM. Sphingosine-1-phosphate and its receptors: Structure, signaling, and influence. Annu Rev Biochem2013; 82(1): 637–662.
11.
WarnkeCMausbergAKStettnerM. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis. Neurology2013; 81(16): 1400–1408.
12.
HohlfeldRStüveO.A bird’s-eye view of T cells during natalizumab therapy. Neurology2013; 81(16): 1372–1373.
13.
SørensenPS.Ozanimod: A better or just another S1P receptor modulator?Lancet Neurol2016; 15(4): 345–347.
14.
CohenJAArnoldDLComiG. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): A randomised, placebo-controlled, phase 2 trial. Lancet Neurol2016; 15(4): 373–381.
